Generate:Biomedicines welcomes Aarif Khakoo, MD, MBA, as chief scientific officer. 01.29.2026 SOMERVILLE, Mass., Jan. 29, 2026 - Generate:Biomedicines ("Generate") today announced the appointment of Aarif Khakoo, MD, MBA, as chief scientific officer. A physician-scientist and experienced biotechnology leader, Dr. Khakoo brings deep expertise in building and scaling platform-driven drug generation engines, with a track record of advancing medicines from discovery through early clinical development. In this role, he will lead scientific and strategic application of The Generate Platform to discover and develop therapeutics across the company's pipeline. "Aarif is a highly respected scientific leader with a rare combination of translational insight, platform vision, and operational rigor," said Mike Nally, chief executive officer of Generate:Biomedicines. "His experience building and scaling innovative discovery engines and advancing programs that translate into the clinic will be instrumental as we continue to expand the capabilities of The Generate Platform and advance our growing pipeline of protein therapeutics." Dr. Khakoo joins Generate from Scribe Therapeutics, where he served as chief scientific officer and head of research and development, leading platform development, biology discovery, and translational research for a next-generation genome editing and epigenetic silencing platform. Previously, he was head of drug development and chief medical officer at Calico Life Sciences, where he both oversaw multiple investigational new drug and clinical trial applications filings and advanced a pipeline of programs across immuno-oncology, neurodegeneration, and kidney disease, while chairing the Calico - AbbVie Joint Steering Committee. Earlier in his career, Dr. Khakoo spent seven years at Amgen, where he founded and led the cardiometabolic disorders therapeutic area and contributed to the discovery and advancement of multiple novel clinical candidates, including programs now in late-stage development and one that has received FDA approval. He also served as head of Amgen's South San Francisco site, overseeing its growth to an R&D hub of approximately 600 employees and chairing Amgen's Early Program Review Committee, which guided the company's early development portfolio. Before transitioning to industry, Dr. Khakoo served on the cardiology faculty at The University of Texas MD Anderson Cancer Center, leading translational research on heart failure and cancer therapy-related cardiotoxicity. He is a board-certified physician, adjunct clinical faculty member at Stanford University, and author of numerous peer-reviewed publications. About Generate:Biomedicines Generate is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better medicines for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline of therapies across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.

Scribe Therapeutics to present at the 44th Annual J.P. Morgan Healthcare Conference. ALAMEDA, Calif.-(BUSINESS WIRE)-#CRISPR-Scribe Therapeutics Inc. (Scribe), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective enough to become standard-of-care treatments for prevalent diseases, today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 8:30 a.m. PT in San Francisco, CA. About Scribe Therapeutics Scribe Therapeutics is revolutionizing medicine by developing optimized in vivo CRISPR-based genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. The company is on a mission to build the first CRISPR-based therapeutics that are effective and safe enough to transform everyone's lifetime risk for disease. Scribe's CRISPR by Design(TM) approach engineers bacterial immune systems into a premier suite of genome and epigenome editing tools built for unique molecular advantages in activity, specificity, and deliverability, enabling the creation of therapies with a broader therapeutic window and safe for use as a preventative treatment. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene, resulting in significant and durable reduction of LDL-C levels. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com. Media Contact: Thermal for Scribe Therapeutics [email protected]